Figure 2

Inhibition of JAK2 attenuates LPS-stimulated release of TNFα and IL-6 from glial cells. A sample immunoblot indicates that expression of phosphorylated JAK2 and STAT1 were enhanced in glial cells treated with LPS (2 h; 100 ng/ml), and that this effect was attenuated when cells were incubated in the presence of a specific JAK2 inhibitor, SAR317461 (2 μM) (A). Expression of phosphorylated IкBα was enhanced in cells that were treated with LPS (B); however, co-incubation of cells with LPS and SAR317461 had no effect on the LPS-induced expression of phosphorylated IкBα (B). The LPS-stimulated release of TNFα at 6 h (C; ^*** P < 0.001; ANOVA; n = 3) was attenuated when cells were co-incubated with LPS and SAR317461 (⁺⁺ P < 0.01; ANOVA; n = 3), whereas inhibition of the LPS-induced expression of phospho-JAK2/STAT1 using SAR317461 enhanced the LPS-induced release of IL-1β at 9 h (D; ⁺⁺⁺ P < 0.001; ANOVA; n = 3). The LPS-induced up-regulation of IL-6 mRNA (E; ^*** P < 0.001; ANOVA; n = 3) was attenuated when cells were co-treated with SAR317461 (E; ⁺⁺⁺ P < 0.001; ANOVA; n = 3) as was the release of IL-6 (F; ⁺⁺⁺ P < 0.001; ANOVA; n = 3).